{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:26:25Z","timestamp":1786980385651,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00702-025-02923-1","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T07:47:54Z","timestamp":1745912874000},"page":"325-333","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Parkinson\u00b4s day-clinic: which patients should be selected and what services should be offered for successful therapy?"],"prefix":"10.1007","volume":"133","author":[{"given":"C.","family":"Buhmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Kalbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Claus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Hilker-Roggendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. W.","family":"Ip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"W\u00fcllner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"2923_CR1","doi-asserted-by":"publisher","first-page":"g1838","DOI":"10.1136\/bmj.g1838","volume":"348","author":"BR Bloem","year":"2014","unstructured":"Bloem BR, Munneke M (2014) Revolutionising management of chronic disease: the ParkinsonNet approach. BMJ 348:g1838","journal-title":"BMJ"},{"issue":"Suppl 1","key":"2923_CR2","first-page":"S36","volume":"84","author":"C Buhmann","year":"2016","unstructured":"Buhmann C, Bass H, Hahne M, Jost W, Redecker C, Schwarz M, Woitalla D (2016) [Parkinson\u2019s disease at the border between inpatient and outpatient care]. Fortschr Neurol Psychiatr 84(Suppl 1):S36\u2013S40","journal-title":"Fortschr Neurol Psychiatr"},{"key":"2923_CR3","unstructured":"Deutsche Parkinson Vereinigung e.V (2019) Parkinson-Tagesklinik - Kriterienkatalog der Deutschen Parkinson Vereinigung e.V. online https:\/\/www.parkinson-vereinigung.de\/files\/Kliniken%20Parkinson\/Checkliste%20Parkinson%20TK_Audithilfe_cb_cf.pdf"},{"key":"2923_CR4","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1212\/01.wnl.0000247740.47667.03","volume":"68","author":"ER Dorsey","year":"2007","unstructured":"Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68:384\u2013386","journal-title":"Neurology"},{"key":"2923_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.lpm.2016.11.009","volume":"46","author":"J Dupouy","year":"2017","unstructured":"Dupouy J, Ory-Magne F, Brefel-Courbon C (2017) [Other care in Parkinson\u2019s disease: psychological, rehabilitation, therapeutic education and new technologies]. Presse Med 46:225\u2013232","journal-title":"Presse Med"},{"key":"2923_CR6","doi-asserted-by":"publisher","first-page":"812","DOI":"10.2522\/ptj.20070265","volume":"88","author":"T Ellis","year":"2008","unstructured":"Ellis T, Katz DI, White DK, DePiero TJ, Hohler AD, Saint-Hilaire M (2008) Effectiveness of an inpatient multidisciplinary rehabilitation program for people with Parkinson disease. Phys Ther 88:812\u2013819","journal-title":"Phys Ther"},{"key":"2923_CR7","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s00702-018-1918-9","volume":"125","author":"O Frundt","year":"2018","unstructured":"Frundt O, Mainka T, Schonwald B, Muller B, Dicusar P, Gerloff C, Buhmann C (2018) The Hamburg Parkinson day-clinic: a new treatment concept at the border of in- and outpatient care. J Neural Transm (Vienna) 125:1461\u20131472","journal-title":"J Neural Transm (Vienna)"},{"key":"2923_CR8","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1055\/a-1083-6316","volume":"88","author":"O Frundt","year":"2020","unstructured":"Frundt O, Veliqi E, Schonwald B, Sychla P, Gerloff C, Buhmann C (2020) [The Hamburg Parkinson day-clinic: a new treatment concept at the border of in- and outpatient care]. Fortschr Neurol Psychiatr 88:362\u2013373","journal-title":"Fortschr Neurol Psychiatr"},{"key":"2923_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s42466-024-00325-4","volume":"6","author":"G Hoglinger","year":"2024","unstructured":"Hoglinger G, Trenkwalder C (2024) Diagnosis and treatment of Parkinson s disease (guideline of the German society for Neurology). Neurol Res Pract 6:30","journal-title":"Neurol Res Pract"},{"key":"2923_CR10","doi-asserted-by":"publisher","first-page":"7102","DOI":"10.1007\/s00415-024-12687-5","volume":"271","author":"F Hopfner","year":"2024","unstructured":"Hopfner F, Hoglinger G, Trenkwalder C (2024) Definition and diagnosis of Parkinson\u2019s disease: guideline Parkinson\u2019s disease of the German society of neurology. J Neurol 271:7102\u20137119","journal-title":"J Neurol"},{"key":"2923_CR11","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1080\/14737175.2020.1771184","volume":"20","author":"SC Lidstone","year":"2020","unstructured":"Lidstone SC, Bayley M, Lang AE (2020) The evidence for multidisciplinary care in Parkinson\u2019s disease. Expert Rev Neurother 20:539\u2013549","journal-title":"Expert Rev Neurother"},{"key":"2923_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.20344\/amp.7070","volume":"29","author":"J Martins","year":"2016","unstructured":"Martins J, Rua A, Vila CN (2016) [Hospital mortality in Parkinson\u2019s disease: retrospective analysis in a Portuguese tertiary centre]. Acta Med Port 29:315\u2013318","journal-title":"Acta Med Port"},{"key":"2923_CR13","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/ane.12694","volume":"136","author":"M Nerius","year":"2017","unstructured":"Nerius M, Fink A, Doblhammer G (2017) Parkinson\u2019s disease in Germany: prevalence and incidence based on health claims data. Acta Neurol Scand 136:386\u2013392","journal-title":"Acta Neurol Scand"},{"key":"2923_CR14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/1941874411427734","volume":"2","author":"O Oguh","year":"2012","unstructured":"Oguh O, Videnovic A (2012) Inpatient management of Parkinson disease: current challenges and future directions. Neurohospitalist 2:28\u201335","journal-title":"Neurohospitalist"},{"key":"2923_CR15","doi-asserted-by":"crossref","unstructured":"Prell T, Siebecker F, Lorrain M, Eggers C, Lorenzl S, Klucken J, Warnecke T, Buhmann C, Tonges L, Ehret R, Wellach I, Wolz M (2020a) Recommendations for Standards of Network Care for Patients with Parkinson\u2019s Disease in Germany. J Clin Med 9","DOI":"10.3390\/jcm9051455"},{"key":"2923_CR16","doi-asserted-by":"crossref","unstructured":"Prell T, Siebecker F, Lorrain M, Tonges L, Warnecke T, Klucken J, Wellach I, Buhmann C, Wolz M, Lorenzl S, Herbst H, Eggers C, Mai T (2020b) Specialized Staff for the Care of People with Parkinson\u2019s Disease in Germany: An Overview. J Clin Med 9","DOI":"10.3390\/jcm9082581"},{"key":"2923_CR17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S1474-4422(14)70055-9","volume":"13","author":"IH Sturkenboom","year":"2014","unstructured":"Sturkenboom IH, Graff MJ, Hendriks JC, Veenhuizen Y, Munneke M, Bloem BR, Nijhuis-van der Sanden MW (2014) Efficacy of occupational therapy for patients with Parkinson\u2019s disease: a randomised controlled trial. Lancet Neurol 13:557\u2013566","journal-title":"Lancet Neurol"},{"key":"2923_CR18","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/bs.irn.2017.05.017","volume":"134","author":"N Titova","year":"2017","unstructured":"Titova N, Chaudhuri KR (2017a) Nonmotor Parkinson\u2019s and future directions. Int Rev Neurobiol 134:1493\u20131505","journal-title":"Int Rev Neurobiol"},{"key":"2923_CR19","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/bs.irn.2017.05.015","volume":"134","author":"N Titova","year":"2017","unstructured":"Titova N, Chaudhuri KR (2017b) Personalized medicine and nonmotor symptoms in Parkinson\u2019s disease. Int Rev Neurobiol 134:1257\u20131281","journal-title":"Int Rev Neurobiol"},{"key":"2923_CR20","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/mds.27027","volume":"32","author":"N Titova","year":"2017","unstructured":"Titova N, Chaudhuri KR (2017c) Personalized medicine in Parkinson\u2019s disease: time to be precise. Mov Disord 32:1147\u20131154","journal-title":"Mov Disord"},{"key":"2923_CR21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00115-018-0590-5","volume":"90","author":"L Tonges","year":"2019","unstructured":"Tonges L, Bartig D, Muhlack S, Jost W, Gold R, Krogias C (2019) [Characteristics and dynamics of inpatient treatment of patients with Parkinson\u2019s disease in Germany: analysis of 1.5 million patient cases from 2010 to 2015]. Nervenarzt 90:167\u2013174","journal-title":"Nervenarzt"},{"key":"2923_CR22","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","volume":"124","author":"OB Tysnes","year":"2017","unstructured":"Tysnes OB, Storstein A (2017) Epidemiology of Parkinson\u2019s disease. J Neural Transm (Vienna) 124:901\u2013905","journal-title":"J Neural Transm (Vienna)"},{"key":"2923_CR23","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1136\/jnnp.74.2.158","volume":"74","author":"DT Wade","year":"2003","unstructured":"Wade DT, Gage H, Owen C, Trend P, Grossmith C, Kaye J (2003) Multidisciplinary rehabilitation for people with Parkinson\u2019s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 74:158\u2013162","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2923_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1474-4422(17)30406-4","volume":"17","author":"JHL Ypinga","year":"2018","unstructured":"Ypinga JHL, de Vries NM, Boonen LHHM, Koolman X, Munneke M, Zwinderman AH, Bloem BR (2018) Effectiveness and costs of specialised physiotherapy given via ParkinsonNet: a retrospective analysis of medical claims data. Lancet Neurol 17:153\u2013161","journal-title":"Lancet Neurol"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-02923-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-025-02923-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-02923-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T13:19:50Z","timestamp":1769692790000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-025-02923-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2923"],"URL":"https:\/\/doi.org\/10.1007\/s00702-025-02923-1","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"16 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CB received a grant from the Hilde-Ulrichs-Stiftung, served as a consultant for Bial, Hormosan Pharma, Merz Pharmaceuticals and Zambon, and received honoraria for scientific presentations from AbbVie, Bial, Stada Pharma, TAD Pharma, UCB Pharma, and Zambon. EK has received grants from the German Ministry of Education and Research, General Joint Committee, Germany, the German Parkinson Society, and STADAPHARM GmbH; honoraria from AbbVie GmbH Germany; memodio GmbH Germany; license fees from Prolog GmbH, Germany. EK is one of the authors of the cognitive intervention series \u201cNEUROvitalis\u201d but receives no corresponding honoraria. IC is receiving grants from Merz Pharmaceuticals, served as a consultant for Abbvie, Stadapharm and Desitin, received honoraria for scientific presentations and\/or travel grants from Abbvie, Stadapharm, Bial, Zambon and Merz Pharmaceuticals. RK is receiving or has received research grants from the Fonds National de Recherche (FNR) Luxembourg, Fondation Veuve-Metz-Tesch Luxembourg, the Leir Foundation, the Michael J. Fox Foundation for Parkinson\u02bcs Research (MJFF), the European Institute of Innovation and Technology (EIT Health), the Innovative Medicines Initiative (IMI) of the European Union and the European pharmaceutical industry, and the European Union\u2019s Horizon 2020 and Horizon Europe research and innovation programs. RK received speaker\u2019s honoraria and\/or travel grants from Abbvie, Bial, Desitin, Medtronic and Zambon. RK is participating or has participated as PI or site-PI for industry sponsored clinical trials without receiving personal honoraria. RHR, CWI, TM and UW did not report any competing interests or funding with respect to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}